SHANGHAI, China, Nov. 9 /PRNewswire/ -- Accelovance, a Rockville, Maryland
based company with a wholly foreign owned enterprise (WFOE) in China
celebrates the opening of an office in Shanghai, its second in the PR China.
With additional presence in China's pharmaceutical market, the Shanghai office
allows Accelovance to broaden its services and expand its capacity for
conducting Phase I-IV clinical trials.
"Accelovance has a growing presence as a full service contract research
organization (CRO) in China and the opening of a new office is evidence of
that. It gives us a greater opportunity to service pharma and biotech
companies on an international level," commented President and CEO Stephen J.
Trevisan. Accelovance will take office space with the State of Maryland in
Shanghai, immediately employing 3-5 clinical personnel. In recent years, the
State of Maryland has proactively worked with locally based companies to
promote growth in emerging markets, such as China. Mary Kane, Maryland's
Secretary of State, agrees, "Maryland has embraced the idea of global
cooperative ventures. Accelovance is an excellent example of future
opportunities for the business community in Maryland and abroad."
Accelovance's Beijing office will continue to serve as the base of
operations for China, managing the new Shanghai location. Operations in China
provide Accelovance's clients with a strategic alternative to their clinical
trial needs and add to the capabilities of an existing 10-site network in the
United States. Dr. Ken Ren, President of Accelovance China noted, "Since our
Beijing office opened in May, our services in China have been well received.
Now with a location in another region of the country, Accelovance is better
positioned to rapidly enroll patients and conduct trials in a cost effective
Headquartered in Rockville, Maryland, Accelovance is a privately held
company that has 10 clinical sites in the United States. In China, the
Company operates through its wholly owned foreign enterprise in Beijing and
has established clinical services in the country. Globally, Accelovance
provides Phase I-IV clinical trial services across a focus of therapeutic
areas that include investigator selection, patient recruitment and study
management services for pharmaceutical, contract research organization (CRO),
and biotechnology industries. The company is focused on optimizing the quality
and productivity of multiple clinical sites, through strong central management
and targeted pro-active patient recruitment. Delivering high quality and
timely clinical trial support services, Accelovance is committed to
understanding and meeting its clients needs to ensure their success.
For more information, visit the company's website at
CONTACT: Garrett D. Smith at 240.238.4914.